Introduction {#Sec1}
============

Diabetes mellitus (DM) is a serious endocrine and metabolic disease. The vast majority of DM cases fall into two broad etiopathogenetic categories \[[@CR1]\]. Type 1 diabetes mellitus (T1DM) accounts for only 5%--10% of all DM cases and is caused by β-cell destruction, usually leading to complete insulin deficiency. Type 2 DM (T2DM) accounts for 90%--95% of all DM cases and is caused by insulin resistance (IR), sometimes accompanied by defects in insulin secretion. Most anti-diabetic drugs exert unwanted side effects (hypoglycemia and gastrointestinal problems) \[[@CR2]\]. There is an urgent need to develop safer and more effective drugs to treat T2DM and insulin resistance.

Changes in cell energy metabolism and nutrient partitioning are responsible for the development of insulin resistance \[[@CR3]\]. Mitochondria generate most of the cell's energy via aerobic respiration and are indispensable for life \[[@CR4]\]. Mitochondrial dysfunction may affect energy production, thereby impairing cell function, and has been implicated in many acute and chronic diseases \[[@CR5]--[@CR7]\]. A strong association of insulin resistance and T2DM development with mitochondrial dysfunction is evident, and mitochondrial dysfunction causes insulin resistance \[[@CR8]--[@CR10]\]. However, the details of this association remain unclear. Some studies have shown that lifestyle interventions (exercise or caloric restriction) increase insulin sensitivity, delaying or preventing diabetes onset, and insulin sensitivity is closely related to increases in mitochondrial mass and oxidative phosphorylation \[[@CR11], [@CR12]\]. A defect in oxidative phosphorylation caused by a reduced number of mitochondria may affect fatty acid metabolism, ultimately causing insulin resistance \[[@CR11], [@CR13]\]. In addition, one study found that a reduction in mitochondrial content was caused by a reduced type I:II muscle fiber ratio \[[@CR13]\]. A few studies on diabetics have reported substantial decreases in mitochondrial volume and obvious abnormalities in mitochondrial morphology, consistent with the mitochondrial ultrastructural changes and decreased oxidative phosphorylation activity evident in T2DM patients \[[@CR14], [@CR15]\]. Together, these data suggest that the mitochondrion may be an important therapeutic target for the treatment of T2DM.

Mitochondrial biogenesis is dynamically regulated; new mitochondria are constantly produced to maintain the appropriate number of morphologically normal active organelles to meet the constantly changing bioenergetic needs of the cell via oxidative metabolism \[[@CR16]\]. Therefore, compounds that stimulate mitochondrial biogenesis may improve mitochondrial dysfunction. Mitochondrial biogenesis is coordinately controlled by transcription factors, nuclear hormone receptors, and transcriptional coactivators. Peroxisome proliferator-activated receptor gamma coactivator 1, a member of the PGC-1 family of transcriptional coactivators, is the master regulator of mitochondrial biogenesis in many tissues \[[@CR17]\]. PGC-1α controls the expression levels of mitochondrial genes and induces mitochondrial biogenesis by interacting with transcription factors such as nuclear respiratory factors (NRFs), peroxisome proliferator-activated receptors, and estrogen receptor-related receptors (ERRs) \[[@CR18]\]. Mitochondrial transcription factor A, a DNA-binding stimulatory protein, regulates mitochondrial DNA transcription and replication to maintain the mitochondrial DNA (mtDNA) content \[[@CR19]\]. PGC-1α interacts with NRF1 to activate mitochondrial transcription factor A (TFAM) expression, thereby stimulating mitochondrial biogenesis \[[@CR20]\]. Furthermore, T2DM development is associated with decreased PGC-1α expression in the liver and skeletal muscle caused by a reduction in PGC-1α-dependent gene expression. This compromises mitochondrial biogenesis and further impairs mitochondrial ATP synthesis \[[@CR21]\]. Overall, mitochondrial biogenesis regulated by PGC-1α may be critical for T2DM treatment.

Catalpol is an iridoid glucoside of *Rehmannia glutinosa* that exerts significant hypoglycemic effects on different diabetic models \[[@CR22], [@CR23]\]. A recent study indicated that orally administered catalpol has beneficial effects on insulin resistance thus lowering blood glucose \[[@CR24]\]. We recently showed that catalpol improved HFD/STZ-induced muscle mitochondrial dysfunction \[[@CR25]\]. Insulin resistance and mitochondrial dysfunction are closely related. Moreover, it is still debated whether catalpol exerts direct mitochondrial protection or insulin-sensitizing effects on skeletal muscles. Although the hypoglycemic effect of catalpol is related to increased mitochondrial function, the detailed molecular mechanism remains unknown. Here, we explored how catalpol improves mitochondrial function in *db/db* mice and C2C12 myotubes.

Materials and methods {#Sec2}
=====================

Materials and reagents {#Sec3}
----------------------

Catalpol (purity \> 99%) was obtained from Nanjing Spring & Autumn Biological Engineering Co., Ltd. (Nanjing, China). Fetal bovine serum was purchased from ExCell Biotech (Cat No: FSP500, Shanghai, China). Fatty acid-free bovine serum albumin (BSA) was obtained from Merck (Kenilworth, NJ, USA). Mito Tracker Red (Molecular Probes) and 2-\[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino\]-2-deoxy-*D*-glucose (2-NBDG) were purchased from Invitrogen (Carlsbad, CA, USA). Other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated.

Animal studies {#Sec4}
--------------

All experimental procedures were conducted in accordance with institutional guidelines for the care and use of laboratory animals in China. Male C57BL KS/J-*db/db* mice (8--9 weeks old, 40--45 g in body weight, *n* = 16 animals) and their normoglycemic littermates (8--9 weeks old, 18--20 g in body weight, *n* = 8 animals) were obtained from the Nanjing University Animal Model Research Center (Nanjing, China). Sixteen C57BLKS/J-*db/db* mice were randomly allocated to the *db/db* mouse group or the 200 mg/kg catalpol-treated group (orally administered for 8 consecutive weeks). All animals were housed in an air-conditioned room maintained at a temperature of 20--23 °C with a 12/12-h light/dark cycle and were provided with standard mouse chow and water *ad libitum*. At the end of the experimental period, all mice were anesthetized using isoflurane following 12 h of fasting. Blood was collected from the inferior vena cava for the determination of glucose, HbA1c, triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels. Then, the mice were killed, and tibialis anterior (TA) muscle sections were collected. The TA muscle sections were used for Western blotting, Rt-qPCR and histological analysis. All dissected tissues were immediately frozen in liquid nitrogen and stored at −80 °C until analysis.

Glucose and insulin tolerance tests {#Sec5}
-----------------------------------

The glucose tolerance test (2.0 g/kg i.p.) was performed in the animals following 6 h of fasting. Serum glucose concentrations were detected by using a glucometer (Bayer Corporation, Mishawaka, IN, USA) at 0, 30, 60, 90, and 120 min after glucose injection. The insulin tolerance test (0.75 IU/kg i.p.) was performed in the animals following 4 h fasting. Serum glucose concentrations were determined using a glucometer at 0, 30, 60, and 120 min after insulin injection. The areas under the curves (AUCs) of the insulin tolerance test results were calculated \[[@CR10]\].

Mitochondrial assays {#Sec6}
--------------------

Mitochondria were separated from fresh TA muscles as previously described \[[@CR25]\]. The relative mitochondrial DNA content was measured by quantitative polymerase chain reaction (PCR) as described previously \[[@CR26]\]. Nuclear β-actin and ND1 were used to represent nDNA and mtDNA. The primer pairs used for PCR are listed in Table [1](#Tab1){ref-type="table"}.Table 1The primers used for real-time quantitative PCR (house mouse, 5'-3').GeneNCBIPGC-1αForwardTATGGAGTGACATAGAGTGTGCTNC_000071.6ReverseCCACTTCAATCCACCCAGAAAGTFAMForwardTGATTGGCACCGATCCTCGNC_000076.6ReverseCCACAGCGTCATATCATCCAGERR-αForwardGACGGCAGAAGTACAAACGGNC_000085.6ReverseCAACCAGCAGATGCGACACNrf1ForwardAGCACGGAGTGACCCAAACNC_000072.6ReverseTGTACGTGGCTACATGGACCTβ-ActinForwardAGGTGTGGTGCCAGATCTTCNC_000071.6ReverseGGACTCCTATGTGGGTGACGND1ForwardCAGCCTGACCCATAGCCATAATATNC_005089.1ReverseTGATTCTCCTTCTGTCAGGTCGAA

Determination of mitochondrial membrane potential and ATP content {#Sec7}
-----------------------------------------------------------------

The mitochondrial membrane potential (Δψm) in the TA muscles of *db/db* mice was evaluated using a JC-1 mitochondrial membrane potential detection kit, as previously described \[[@CR26]\]. The ATP content of the isolated mitochondria was determined using a Cell Titer-Glo® 2.0 Assay Kit (Promega, Madison, WI, USA) according to the manufacturer's instructions.

Electron microscopy {#Sec8}
-------------------

Fresh TA muscles were immediately fixed with cold 2.5% glutaraldehyde in phosphate-buffered saline (PBS, pH = 7.4). All samples were processed, as previously described \[[@CR10]\]. Images were acquired using a JEM-1010 electron microscope (Jeol USA Inc., Peabody, MA, USA). For each group, the number of mitochondria was assayed from 24 images from 8 animals using Image-Pro Plus software (Media Cybernetics, Rockville, MD, USA).

Cell culture {#Sec9}
------------

C2C12 cells were purchased from the American Tissue Culture Collection (ATCC) and grown in DMEM growth medium (Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin) in a 5% CO~2~ incubator at 37 °C as previously described \[[@CR27]\]. Confluent C2C12 myoblasts were differentiated into myotubes by switching the medium to medium containing 2% horse serum and 1% penicillin/streptomycin when the cells reached 90%--100% confluency. Differentiated myotubes were serum-starved overnight and then incubated in serum-free media containing 10, 30, or 100 μM catalpol or 1 mM metformin. Stimulated myotubes were collected for Western blotting or real-time PCR. Differentiated myotubes were incubated in serum-free medium containing 2 μM compound C for 2 h and then incubated in new serum-free medium containing 10, 30, or 100 μM catalpol or 1 mM metformin for 24 h as described in our previous report \[[@CR22]\].

Glucose uptake activity measurement using 2-NBDG {#Sec10}
------------------------------------------------

Glucose uptake activity in myotubes was measured using 2-NBDG, as described previously \[[@CR28]\]. Briefly, myotubes were washed with cold PBS and incubated in glucose-free DMEM with 60 μM 2-NBDG for 1 h. Then, the myotubes were washed twice with cold PBS to remove free 2-NBDG. Finally, the myotubes were suspended in cold PBS and transferred to the wells of a 96-well fluorescence microplate.

Mitochondrial staining {#Sec11}
----------------------

Following incubation with 50 mM D-glucose for 24 h and treatment with catalpol, cells were stained with 100 nM Mito-Tracker Red for 30 min at 37 °C, as described in our previous report \[[@CR22]\]. Mitochondria were visualized under a confocal microscope, and the images were analyzed using Image-Pro Plus software (Media Cybernetics, Rockville, MD, USA).

Real-time quantitative polymerase chain reaction (PCR) {#Sec12}
------------------------------------------------------

Total RNA was extracted from the TA muscle using TRIzol reagent and an RNeasy Kit (Vazyme Biotech, Nanjing, China) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized from total RNA using a cDNA Synthesis Kit (Vazyme Biotech, Nanjing, China). The resulting cDNAs were amplified using a SYBR Green Master Mix Kit in an iQ™5 real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA, USA), as reported previously \[[@CR29]\]. Gene expression was evaluated via the ΔΔCT method using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a reference gene. The primer pairs used for PCR are listed in Table [1](#Tab1){ref-type="table"}.

Western blot analysis {#Sec13}
---------------------

Excised TA muscles were dissolved in total protein extraction buffer (keyGEN Biotech, Nanjing, China) with protease and phosphatase inhibitors. The total protein (30 μg) was fractionated on 6--12% sodium dodecyl sulfate (SDS) polyacrylamide gels and transferred to nitrocellulose membranes (Millipore, Billerica, MA, USA) by electroblotting. The membranes were blocked in Tris-buffered saline containing 5% milk and then incubated overnight at 4 °C with one of the following primary antibodies: rabbit anti-TFAM (Cat No: ab131607, Abcam, Cambridge, MA, USA), rabbit anti-PGC-1α (Cat No: 19142-1, Abcam), rabbit anti-PFKP (Cat No: 8164T, CST, Danvers, MA, USA), rabbit anti-phosphor-ACC (Cat No: 3661s, CST), rabbit anti-ACC (Cat No: 3662s, CST), rabbit anti-COX 1 (Cat No: A6564, ABclonal, Wuhan, Hubei, China), rabbit anti-NDUFS3 (Cat No: A8013, ABclonal), rabbit anti-SDHA (Cat No: A2594, ABclonal), rabbit anti-ATP5A1 (Cat No: A5884, ABclonal), rabbit anti-UQCRC2 (Cat No: A4184, ABclonal), mouse anti-GAPDH (Cat No: sc-32233, Santa Cruz, Felton, CA, USA) or mouse anti-β-actin (Cat No: sc-69879, Santa Cruz).

Immunohistochemistry {#Sec14}
--------------------

For immunohistochemistry, TA muscle samples were fixed in 4% paraformaldehyde (PFA), and paraffin-embedded sections were incubated overnight at 4 °C with a primary antibody against myosin heavy chain II (MY-32) (1:100; ab51263, Abcam, Cambridge, MA, USA) \[[@CR30]\]. Stained tissues were examined under a light microscope (BX53, Olympus, Japan).

Statistical analysis {#Sec15}
--------------------

All obtained data were analyzed with one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison posttest using GraphPad 6.0 (Graph-pad Software Inc., San Diego, CA, USA). Data are presented as the mean ± SD. Values with *P* *\<* 0.05 were considered statistically significant.

Results {#Sec16}
=======

Catalpol lowers fasting blood glucose levels and ameliorates mitochondrial dysfunction in the skeletal muscle of *db/db* mice {#Sec17}
-----------------------------------------------------------------------------------------------------------------------------

Body weight and the serum levels of glucose, HbA1c, TG, TC, and LDL-C were increased in the *db/db* mice compared with the control mice, whereas, the serum level of HDL-C was decreased in the *db/db* mice. Catalpol treatment decreased the serum levels of glucose, HbA1c, TC, and LDL-C (Table [2](#Tab2){ref-type="table"}). Moreover, catalpol treatment increased insulin sensitivity (Fig. [1a, b](#Fig1){ref-type="fig"}) but had no effect on glucose tolerance (Fig. [1c](#Fig1){ref-type="fig"}). As we reported previously, catalpol improved skeletal muscle mitochondrial function \[[@CR25]\]. The mitochondrial membrane potential of the skeletal muscle of *db/db* mice was 60% lower than that of control mice but increased after catalpol treatment (Fig. [1d](#Fig1){ref-type="fig"}). As glucose utilization and mitochondrial activity are associated with changes in ATP production \[[@CR31]\], we performed an ATP assay to evaluate mitochondrial function. The catalpol treatment of *db/db* mice increased ATP production (Fig. [1e](#Fig1){ref-type="fig"}). Although the mtDNA copy number was only slightly reduced in the skeletal muscle of *db/db* mice, catalpol markedly increased the mtDNA level (Fig. [1f](#Fig1){ref-type="fig"}). To explore whether catalpol increases the number of mitochondria in mouse skeletal muscle, we assessed both mitochondrion numbers and morphology via electron microscopy. The number of mitochondria was lower in *db/db* mice than in control mice. After the catalpol treatment of *db/db* mice, the mitochondrion number increased, but mitochondrial morphology was abnormal. The skeletal muscles of the *db/db* mice contained abundant lipid droplets, reflecting ectopic lipid deposition (Fig. [1g, h](#Fig1){ref-type="fig"}). Mitochondrial dynamics are usually associated with quality control and the functional maintenance of bioenergetics \[[@CR32]\]. The expression levels of three genes associated with mitochondrial biogenesis (PGC-1α, NRF1, and TFAM) were markedly decreased in the skeletal muscle of *db/db* mice, but these decreases were reversed by catalpol (Fig. [1i](#Fig1){ref-type="fig"}), as revealed by Western blotting (Fig. [1j, k](#Fig1){ref-type="fig"}).Table 2Blood biochemical parameters.CON*db/db*CatalpolGlucose (mmol/L)5.3 ± 1.529.1 ± 3.7^\*\*\*^20.2 ± 4.4^\*\#^Body weight (g)28.5 ± 1.247.1 ± 3.2^\*\*\*^48.3 ± 2.9^\*\*\*^HbA1c (%)3.29 ± 0.636.64 ± 0.65^\*^4.2 ± 0.43^\#^TG (mmol/L)1.17 ± 0.191.66 ± 0.15^\*^1.41 ± 0.12TC (mmol/L)0.73 ± 0.051.13 ± 0.2^\*^0.78 ± 0.11^\#^HDL-C (mmol/L)1.15 ± 0.210.75 ± 0.18^\*\*^1.02 ± 0.33LDL-C (mmol/L)1.33 ± 0.292.87 ± 0.38^\*\*^1.21 ± 0.44^\#^Data are means ± SD, with *n* = 8 per group. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001 compared with controls; ^\#^*P* \< 0.05 vs. *db/db*. *CON* control mice, *db/db* *db/db* mice, *Catalpol* *db/db* mice treated with Catalpol, *TG* triglyceride, *TC* cholesterol, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterolFig. 1Catalpol increases mitochondrial biogenesis in *db/db* mice.**a** The insulin tolerance results and **b** the areas under the curves (AUCs) for the insulin tolerance test are shown. **c** The glucose tolerance results from the glucose tolerance test are shown. **d** Mitochondrial membrane potential, **e** ATP production, and **f** mtDNA copy number were determined in the TA muscle of *db/db* mice. **g** Representative electron micrographs of mitochondria in the TA muscle. Red arrowheads: mitochondria; blue arrowheads: lipid droplets. Scale bar, 500 nm. **h** The number of mitochondria calculated using Innerview 2.0 software (Lumenera). **i** The relative mRNA levels of PGC-1α, TFAM, ERR-α, and NRF1 measured by RT-qPCR. GAPDH served as the control housekeeping gene. **j**, **k** PGC-1α and TFAM protein levels in mouse TA muscle measured by Western blot analysis. The data are expressed as the means ± SD (*n* = 8 animals), \**P* \< 0.05, \*\*\**P* \< 0.001 vs. control mice; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. *db/db* mice.

Catalpol ameliorates the abnormal muscle fiber ratio in *db/db* mice {#Sec18}
--------------------------------------------------------------------

Recent evidence has shown that a shift in the muscle fiber type from oxidative type I to the more glycolytic type II damages the muscles of obese subjects with impaired glucose tolerance \[[@CR33]\]. We quantified the muscle fiber types by immunohistochemical staining of TA muscle sections and assessed the findings. The proportion of myosin heavy chain I (MHC I) fibers was decreased, whereas the proportion of MHC II fibers was significantly increased in *db/db* mice compared with control mice (Fig. [2a](#Fig2){ref-type="fig"}). However, the proportions of MHC I and II fibers did not differ between the catalpol treatment and control groups (Fig. [2b, c](#Fig2){ref-type="fig"}). Catalpol increased the proportion of MHC I fibers and decreased that of MHC II fibers in *db/db* mice. In addition, the p-AMPK/t-AMPK and p-ACC/t-ACC protein ratios were notably increased in *db/db* mice after catalpol treatment. (Fig. [2d, e](#Fig2){ref-type="fig"}). To further demonstrate that catalpol could cause a switch from glycolysis back to oxidative phosphorylation in *db/db* mice, we examined these two types of metabolism in the TA muscle. Regarding glycolysis, the protein level of PFKP (Fig. [2f, g](#Fig2){ref-type="fig"}) and the lactate level (Fig. [2h](#Fig2){ref-type="fig"}) in the TA muscle did not differ between the *db/db* group and the control group. To examine oxidative phosphorylation, we detected the protein expression of the OXPHOS subunits, including NDUFS1 (Complex I), SDHA (Complex II), UQCRC1 (Complex III), COX1 (Complex IV), and ATP5A1 (Complex V). The levels of these proteins were markedly decreased in the TA muscle of *db/db* mice, but these decreases were reversed by catalpol (Fig. [2i, j](#Fig2){ref-type="fig"}).Fig. 2Catalpol prevents the transformation of muscle fiber types in *db/db* mice.**a** TA muscles stained with an anti-MHC II antibody and visualized under a light microscope (magnification 200 × ). The percentages of **b** MHC I-positive and **c** MHC II-positive areas calculated using Innerview 2.0 software. **d**, **e** Western blot analysis using anti-phospho-Thr172-AMPK, anti-AMPK, anti-phospho-Ser79-Acetyl-CoA (ACC) and anti-ACC antibodies to measure protein levels in the TA muscle of *db/db* mice. **f**, **g** PFKP protein levels in the TA muscle. **h** lactate levels in the TA muscle. **i**, **j** The protein levels of NDUFS1 (Complex I), SDHA (Complex II), UQCRC1 (Complex III), COX1 (Complex IV), and ATP5A1 (Complex V) measured by Western blot analysis. The data are expressed as the means ± SD (*n* = 3 animals), \**P* *\<* 0.05, \*\*\**P* *\<* 0.001 vs. control mice; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. *db/db* mice.

Catalpol increases mitochondrial biogenesis in C2C12 myotubes {#Sec19}
-------------------------------------------------------------

To further examine the effects of catalpol on mitochondrial activity, we performed an ATP assay. Catalpol increased ATP production in a dose-dependent manner (Fig. [3a](#Fig3){ref-type="fig"}) and markedly increased the mtDNA copy number in C2C12 myotubes (Fig. [3b](#Fig3){ref-type="fig"}). Thus, catalpol may increase mitochondrial biogenesis in skeletal muscle. Moreover, consistent with the in vivo results (Fig. [2d, e](#Fig2){ref-type="fig"}), catalpol significantly increased the p-AMPK/t-AMPK and p-ACC/t-ACC protein ratios in C2C12 myotubes (Fig. [3c](#Fig3){ref-type="fig"}). PGC-1α and TFAM protein levels were also increased after catalpol treatment in C2C12 myotubes (Fig. [3d](#Fig3){ref-type="fig"}).Fig. 3Catalpol increases mitochondrial biogenesis in C2C12 myotubes.**a** ATP production and **b** the mtDNA copy number were measured in C2C12 myotubes exposed to catalpol for 24 h. **c** Western blot analysis using anti-phospho-Thr172-AMPK, anti-AMPK, anti-phospho-Ser79-ACC and anti-ACC antibodies to determine protein levels and the ratios of p-AMPK/t-AMPK and p-ACC/t-ACC. **d** Western blot analysis of PGC-1α and TFAM (CON: control group; Met: metformin 1 mM). Values are expressed as the means ± SD (*n* = 3), \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs. control.

Catalpol ameliorates the mitochondrial dysfunction induced by high glucose levels in C2C12 myotubes {#Sec20}
---------------------------------------------------------------------------------------------------

Although catalpol treatment increased mitochondrial biogenesis in C2C12 myotubes, whether catalpol protects C2C12 myotubes against high-glucose (HG)-induced mitochondrial dysfunction remained unknown. We used 50 mM glucose to simulate an HG environment in C2C12 myotubes. To explore whether catalpol inhibits HG-induced mitochondrial fragmentation, we used Mito-Tracker Red staining to monitor mitochondrial morphology. In C2C12 myotubes cultured with a normal level of glucose (1000 mg/L), the mitochondria were intact and elongated. In contrast, the mitochondria were shorter and fragmented following HG treatment (Fig. [4a](#Fig4){ref-type="fig"}). The p-AMPK/t-AMPK and p-ACC/t-ACC protein ratios were significantly decreased in HG-treated C2C12 myotubes, and this effect was reversed by catalpol or metformin treatment (Fig. [4b](#Fig4){ref-type="fig"}). Additionally, catalpol significantly increased the protein levels of PGC-1α and TFAM compared with their levels in the HG group (Fig. [4c](#Fig4){ref-type="fig"}).Fig. 4Catalpol protects against HG-induced mitochondrial dysfunction.**a** C2C12 myotubes stained with Mito-Tracker (red) and visualized by fluorescence microscopy after exposure to HG (50 mM), as described in the Methods (magnification, ×400). Cell nuclei were stained with DAPI (blue). **b** Western blot analysis using anti-phospho-Thr172-AMPK, anti-AMPK, anti-phospho-Ser79-ACC and anti-ACC antibodies to determine protein levels and the ratios of p-AMPK/t-AMPK and p-ACC/t-ACC. **c** Western blot analysis of PGC-1α and TFAM (CON: control group; Met: metformin 1 mM). Values are expressed as the means ± SD (*n* = 3), \**P* \< 0.05, \*\**P* \< 0.01 vs. control; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. HG.

The hypoglycemic effect of catalpol is decreased by AMPK inhibitors {#Sec21}
-------------------------------------------------------------------

Prior studies have suggested that AMPK is important for the maintenance of mitochondrial function \[[@CR34], [@CR35]\]. We found that the p-AMPK/t-AMPK protein ratio increased notably after catalpol treatment both in vivo (Fig. [2d, e](#Fig2){ref-type="fig"}) and in vitro (Fig. [3c](#Fig3){ref-type="fig"}). To explore the role of AMPK in the hypoglycemic effect of catalpol, compound C, an AMPK inhibitor, was used to block AMPK phosphorylation in C2C12 myotubes (Fig. [5a](#Fig5){ref-type="fig"}). As expected, both glucose consumption and ATP production decreased following the inhibition of AMPK-mediated phosphorylation. Both catalpol and metformin increased glucose consumption and ATP production via the activation of AMPK signaling (Fig. [5c](#Fig5){ref-type="fig"}). Notably, the catalpol-induced increases in PGC-1α and TFAM protein levels decreased after AMPK inhibition (Fig. [5b](#Fig5){ref-type="fig"}). Strict regulation of AMPK phosphorylation is essential for optimal mitochondrial function \[[@CR36]\]. Thus, AMPK may play an important role in the hypoglycemic effect of catalpol.Fig. 5The hypoglycemic effect of catalpol is achieved by increased AMPK-mediated mitochondrial biogenesis.Differentiated myotubes were incubated in serum-free media with 2 μM compound C for 2 h and then in fresh serum-free media with 10, 30, or 100 μM catalpol, or with 1 mM metformin, for 24 h. **a** Protein levels of p-AMPK (upper panel) and t-AMPK (lower panel). **b** Western blot analysis of PGC-1α and TFAM in C2C12 myotubes. **c** Effect of catalpol on 2-NBDG uptake and ATP production by C2C12 myotubes. Values are expressed as the means ± SD (*n* = 3), \**P* \< 0.05 vs. control. ^\#^*P* \< 0.05.

Discussion {#Sec22}
==========

Previous studies have shown that catalpol effectively lowers fasting blood glucose levels in rodent models of type 1 DM and T2DM \[[@CR25], [@CR37]\]. Consistent with these works, we also found that catalpol significantly reduced blood glucose levels in *db/db* mice. Moreover, we identified a novel molecular mechanism by which catalpol lowers blood glucose levels. Using *db/db* mice and C2C12 cells, we showed that catalpol increases mitochondrial biogenesis by activating the AMPK/PGC-1α/TFAM signaling pathway, which improves both mitochondrial function and glucose homeostasis in skeletal muscle (Fig. [6](#Fig6){ref-type="fig"}). Overall, AMPK/PGC-1α/TFAM signaling plays a vital role in the hypoglycemic effect of catalpol.Fig. 6Hypoglycemic mechanism of catalpol in *db/db* mouse skeletal muscle.Catalpol increased AMPK/PGC-1α/TFAM-mediated mitochondrial biogenesis in skeletal muscle cells. Increased mitochondrial biogenesis resulted in increased glucose uptake and ATP production in skeletal muscle cells.

Mitochondrial dysfunction and insulin resistance are closely related; insulin resistance can trigger mitochondrial dysfunction in the liver and skeletal muscle \[[@CR38]\], and mitochondrial injury can develop after insulin resistance is established \[[@CR39]\]. Therefore, increased mitochondrial function is critical for improving insulin resistance. We found that mitochondrial function was impaired in the skeletal muscle of *db/db* mice. After catalpol treatment, mitochondrial biogenesis was markedly increased. Catalpol also ameliorated mitochondrial dysfunction induced by HG in skeletal muscle cells. Together, the results show that catalpol increased mitochondrial biogenesis, thereby ameliorating mitochondrial impairment in skeletal muscle. Thus, catalpol increased glucose uptake and ATP production by skeletal muscle, reducing the blood glucose level.

It is generally acknowledged that AMPK, a sensor of cellular energy status, serves as a key regulator of glucose uptake, fatty acid oxidation, and mitochondrial biogenesis \[[@CR40]\]. AMPK is a well-known upstream regulator of PGC-1α expression in skeletal muscle. AMPK activation increases the expression and phosphorylation of PGC-1α, further stimulating mitochondrial biogenesis \[[@CR41]\]. As mentioned above, the activation of mitochondrial biogenesis may be useful to treat T2DM and/or insulin resistance. Previous studies have suggested that AMPK stimulates mitochondrial biogenesis and β-oxidation via PGC-1α upregulation in skeletal muscle \[[@CR34], [@CR42]\]. Upregulated expression of AMPK and PGC-1α increased mitochondrial function and muscle glucose metabolism, as shown using both glucose uptake and ATP assays, suggesting a strong association between AMPK activity and the hypoglycemic effects of catalpol. Additionally, the hypoglycemic effect was reduced when catalpol was coadministered with compound C (an AMPK inhibitor). Thus, AMPK-mediated mitochondrial biogenesis may be crucial for the hypoglycemic effect of catalpol.

The regulation of mitochondrial replication and biogenesis increases mitochondrial function. Mitochondria play vital roles in diverse metabolic pathways \[[@CR12], [@CR43], [@CR44]\]. PGC-1α stimulates oxidative metabolism and increases the number of mitochondria. PGC-1α is strongly expressed in the skeletal muscle, heart, white adipose tissue, and brain, all of which are highly oxidative tissues \[[@CR45]\]. We found that *db/db* mice exhibited decreased PGC-1α and TFAM levels in skeletal muscle, consequently, reductions in mitochondrial biogenesis and the number of mitochondria. Additionally, *db/db* mice exhibited a lower mitochondrial membrane potential and ATP production in skeletal muscle. Our results are consistent with earlier data showing mitochondrial dysfunction and reduced mitochondrial biogenesis in the skeletal muscles of *db/db* mice. Catalpol increased the protein levels of both PGC-1α and TFAM in the skeletal muscle of *db/db* mice and C2C12 myotubes, consistent with the observed increases in mtDNA copy number. We found that PGC-1α/TFAM-mediated mitochondrial biogenesis may play a vital role in the hypoglycemic effect of catalpol.

In summary, mitochondrial dysfunction was evident in the skeletal muscle of *db/db* mice. The catalpol-induced activation of AMPK/PGC-1α/TFAM signaling increased mitochondrial biogenesis in skeletal muscle, thereby increasing glucose uptake and ATP production. Hence, skeletal muscle mitochondria may be a useful target for the treatment of T2DM.
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